Laboratory Changes During Dupilumab Treatment for Atopic Dermatitis
Introduction: Dupilumab is an IL-4/IL-13 inhibitor monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD) with remarkable safety and efficacy profiles. However, former studies have reported an increase in serum eosinophils during treatment, with undetermined clin...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-05-01
|
| Series: | Actas Dermo-Sifiliográficas |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0001731024010597 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!